Skip to main content

H.C. Wainwright Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)

Tipranks - Tipranks - Thu Nov 6, 2025

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $17.00. The company’s shares closed yesterday at $14.27.

Meet Your ETF AI Analyst

He CFA covers the Healthcare sector, focusing on stocks such as Solid Biosciences, Nektar Therapeutics, and Satellos Bioscience. According to TipRanks, He CFA has an average return of 33.7% and a 53.28% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aurinia Pharmaceuticals with a $14.00 average price target, implying a -1.89% downside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $17.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $16.20 and a one-year low of $6.55. Currently, Aurinia Pharmaceuticals has an average volume of 1.8M.

Read More on AUPH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).